Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group
| Autor: | Charalambos Deliveliotis, Dimitra Molyva, Dionisios Mitropoulos, Athanasios Papatsoris, C. Kalofonos, Meletios A. Dimopoulos, Stavros D. Peroukidis, Ioannis Adamakis, Kimon Tzannis, Konstantinos Stravodimos, Vassiliki Pissanidou, Nikolaos Pistamaltzian, Georgia Milaki, Athanasios Dellis, Vasilis Karavasilis, Ioannis M. Varkarakis, Nikos Androulakis, Constantinos Constantinides, Ilias Athanasiadis, Iraklis Mitsogiannis, Aristotelis Bamias, Charalambos Andreadis |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Oncology Male Cancer Research chemistry.chemical_compound 0302 clinical medicine transitional cell carcinoma third-generation vinca alcaloid Pharmacology (medical) media_common education.field_of_study Vinflunine Middle Aged Tubulin Modulators 030220 oncology & carcinogenesis second line therapy Female medicine.medical_specialty Population Antineoplastic Agents Vinblastine survival Clinical Reports 03 medical and health sciences Internal medicine medicine media_common.cataloged_instance Humans European union education Adverse effect Survival analysis Aged Retrospective Studies Pharmacology Bladder cancer Performance status business.industry prognostic factors Retrospective cohort study medicine.disease Survival Analysis Surgery 030104 developmental biology chemistry Urinary Bladder Neoplasms Neoplasm Recurrence Local Urothelium business |
| Zdroj: | Anti-Cancer Drugs |
| ISSN: | 1473-5741 0959-4973 |
| Popis: | Relapsed urothelial cancer represents an unmet medical need. Vinflunine is a third-generation antimicrotubuline inhibitor and is currently the only approved drug for second-line treatment across the European Union. We conducted a retrospective analysis assessing the efficacy and safety of vinflunine in 71 Greek patients with relapsed urothelial cancer who were treated between 2005 and 2014. An overall 84% of our patients received vinflunine as second-line treatment, 77% had a performance status of Eastern Cooperative Oncology Group scale 0 or 1, and 30% had liver metastasis at the time of vinflunine administration. A median of four cycles of vinflunine were administered (range 1-16). The most common reported adverse events were constipation, fatigue, and anemia. Median progression-free survival was 6.2 months (95% confidence interval: 4.4-8.8) and overall survival was 11.9 months (95% confidence interval: 7.4-21). Two patients (3%) achieved a complete remission, seven a partial remission (10%), and 22 (31%) had stable disease according to an intention-to-treat analysis. Hemoglobin level less than 10 g/dl and Eastern Cooperative Oncology Group performance status greater than 1 were independent adverse prognostic factors. Stratification according to the Bellmunt risk model was also associated with progression-free survival and overall survival in our population. Vinflunine appears to be a safe and effective treatment modality for relapsed urothelial cancer. More effective therapies and more accurate prognostic algorithms should be sought. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|